RGCC Unveils Revolutionary Cancer Detection Test, Onco-D-clare
Posted: 8th April 2024
Categories: RGCC news
RGCC announces the launch of Onco-D-clare, a groundbreaking cancer detection test that marks a significant milestone in early cancer screening. Utilizing the cutting-edge technology of molecular biology coupled with artificial neural networks, this innovative test empowers individuals to detect cancer before symptoms manifest. Onco-D-clare operates by isolating peripheral blood mononuclear cells from blood samples, followed […]
We are delighted to announce that RGCC has received prestigious recognition as one of the top 10 Swiss Biotech companies in 2023 by Life Sciences Review. Proudly standing alongside Switzerland’s esteemed biotech leaders, this acknowledgment underscores our unwavering commitment to innovation, excellence, and our continual contribution to the life sciences sector. It also reflects our […]
Genetic mutation could hold the key to new breast cancer treatments
Posted: 3rd May 2022
Categories: Industry news
Scientists have identified a mutated gene that causes breast cancer to become more aggressive and spread to other parts of the body in up to 30% of patients. The discovery provides exciting new avenues to develop new treatments for breast cancer, including more effective personalised approaches. Hormone therapy effectively treats around two-thirds of breast cancers, […]
German scientists have identified the proteins inside colon cancer cells that trick the immune system from seeing them as a threat. But, in lab tests, once researchers blocked the signals from the cells, the immune systems began to attack them. The insight could help scientists develop new and highly targeted immunotherapies for one of the […]
New tumour biobank powers personalised cancer treatments
Posted: 22nd March 2022
Categories: Industry news
Scientists have discovered new and more effective ways of growing breast cancer tumours that could accelerate research and the development of new treatments. Instead of transplanting human tumours into mice, they’ve developed a bank of “human patient-derived xenografts (PDXs)” that can be used to screen drugs. Used alongside personalised genetic tests could improve cancer treatment […]
SOTs effective at treating cancer in 77% of patients
Posted: 9th March 2022
Categories: RGCC news
Cancer patients treated with the highly targeted supportive oligonucleotide therapy (SOT) showed benefits in 77% of cases, RGCC scientists have found. A new paper published in the in vivo journal finds evidence that SOTs effectively target and kill cancer cells on their own or in tandem with other therapies. Supportive oligonucleotide therapy is an advanced, […]
Mutated BRCA genes raise prostate and pancreatic cancer risk
Posted: 28th February 2022
Categories: Industry news, RGCC news
Mutations in BRCA1 and BRCA2 genes increase the risk of breast cancer but may also cause prostate and pancreatic cancers in men, Cambridge University scientists have discovered. After studying the medical history of thousands of families, the team found that 27% of men who carry a BRCA 2 mutation will develop prostate cancer, and those […]
Scientists studying the cell replication process have discovered that damage to DNA during the early stages could potentially create “genomic instability” that could cause cancer. The cutting-edge research into cell replication has implications for future research and could, in time, lead to the development of new strategies for diagnosing and treating cancer. Cells in the […]
Scientists at the Sloan Kettering Institute have engineered a new range of immunotherapies that target not only cancer cells with specific markers but cancer cells surrounding the tumour site. Described by researchers as a “micropharmacy” in the body, the new cells offer hope for those with cancers that evade treatment with immunotherapies or for whom […]
USCF researchers have developed a new way of looking at cancer immunotherapies, matching the immune environment around the tumour site. The research time analysed 364 individual tumours across 12 cancer types, identifying a range of immune cells such as macrophages, NK and B cells that could be potential targets for new immunotherapies. The discovery opens […]
Scientists worldwide are doing incredible things to improve the diagnosis and treatment of all forms of cancer. New approaches such as targeted immunotherapies are opening up new avenues for cancer treatment that prove highly effective. At RGCC, we’ve pioneered the use of personalised genetic testing for cancer diagnosis, and others are listening with the NHS […]
CTCs accurate predictor of chemotherapy resistance
Posted: 10th December 2021
Categories: Industry news
Liquid biopsy tests before and during chemotherapy can accurately detect whether patients with prostate cancer are resistant to treatment with anti-cancer drug docetaxel, scientists have found. By analysing a blood test for circulating tumour cells (CTCs), researchers were able to identify patients who are resistant to docetaxel treatments. Identifying patterns in the data can predict […]
